SCHEMBL18495331

SCHEMBL18495331

CC(C)(C)COC(=O)N[C@@H](CO)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 3/20 0.49
MME P08473 5/20 0.44
CTSK P43235 3/20 0.42
ITGAV P06756 2/20 0.41
ITGB3 P05106 2/20 0.41
TSHR P16473 2/20 0.36
LMNA P02545 1/20 0.36
CYP3A4 P08684 1/20 0.36
NFKB1 P19838 1/20 0.36
ADRA1A P35348 1/20 0.36
RAB9A P51151 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
KMT2A Q03164 1/20 0.36
CTSL P07711 2/20 0.35
CTSB P07858 2/20 0.35
CTSS P25774 2/20 0.35
ITGB6 P18564 1/20 0.34
CA2 P00918 2/20 0.33
CA1 P00915 1/20 0.33
ITGA2B P08514 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7034093 0.84 CTSK (0.41) TGFBR1CTSKITGAVITGB3TSHR
SCHEMBL7034097 0.84 CTSK (0.41) TGFBR1CTSKITGAVITGB3TSHR
SCHEMBL10460580 0.82 TGFBR1 (0.47) TGFBR1MMEKMT2ACA2CA1
SCHEMBL28836296 0.82 TGFBR1 (0.47) TGFBR1MMEKMT2ACA2CA1
SCHEMBL17224588 0.79 TGFBR1 (0.53) TGFBR1MMEITGAVITGB3LMNA
SCHEMBL28009494 0.79 TGFBR1 (0.53) TGFBR1MMEITGAVITGB3LMNA
SCHEMBL28710585 0.79 TGFBR1 (0.53) TGFBR1MMEITGAVITGB3LMNA
SCHEMBL3098916 0.78 TGFBR1 (0.45) TGFBR1MMEITGB3KMT2AITGA2B
SCHEMBL47290 0.78 TGFBR1 (0.52) TGFBR1CTSKKMT2ACTSLCTSB
SCHEMBL47301 0.78 TGFBR1 (0.52) TGFBR1CTSKKMT2ACTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11185594-B2 (Anti-HER2 antibody)-drug conjugate DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-11-30 US disclosed
EP-3130608-B1 (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE DAIICHI SANKYO CO LTD (JP) 2019-09-04 EP disclosed
EP-3130608-A1 (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE Daiichi Sankyo Co., Ltd. (JP) 2017-02-15 EP disclosed
US-20170035906-A1 (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170035906-A1 (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE ERBB2, EGFR, LANCL2 TGFBR1 1542/4885MME 630/4885CTSK 2204/4885
US-11185594-B2 (Anti-HER2 antibody)-drug conjugate ERBB2, EGFR, LANCL2 TGFBR1 1542/4885MME 630/4885CTSK 2204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.